What is Lexaria Bioscience's operating income?

Lexaria Bioscience's total operating income in 2025 was -$11.88 million, based on the following breakdown: Total Gross Profit: $703.20 thousand Total Operating Expenses: $12.58 million

Lexaria Bioscience (LEXX) Financials

$0.58 -0.02 (-3.17%)

As of 10:35 AM Eastern

Compare

Annual Income Statements for Lexaria Bioscience

This table shows Lexaria Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	8/31/2015	8/31/2016	8/31/2017	8/31/2018	8/31/2019	8/31/2020	8/31/2021	8/31/2022	8/31/2023	8/31/2024	8/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-1.77	-1.21	-1.87	-6.60	-4.10	-3.93	-4.03	-7.27	-6.66	-5.80	-12
Consolidated Net Income / (Loss)	-1.93	-1.28	-1.93	-6.61	-4.16	-4.08	-4.19	-7.38	-6.71	-5.81	-12
Net Income / (Loss) Continuing Operations	-1.98	-1.28	-1.93	-6.61	-4.16	-4.15	-4.16	-7.38	-6.67	-5.81	-12
Total Pre-Tax Income	-1.98	-1.28	-1.93	-6.61	-4.16	-4.15	-4.16	-7.38	-6.67	-5.81	-12
Total Operating Income	-1.98	-1.27	-1.92	-6.61	-4.16	-4.15	-4.16	-6.62	-6.53	-5.75	-12
Total Gross Profit	-0.02	-0.00	0.03	0.41	0.20	0.22	0.55	0.18	0.19	0.46	0.70
Total Revenue	0.01	0.04	0.06	0.43	0.22	0.31	0.72	0.26	0.23	0.46	0.71
Operating Revenue	0.01	0.04	0.06	0.43	0.22	0.31	0.72	0.26	0.23	0.46	0.71
Total Cost of Revenue	0.03	0.05	0.03	0.03	0.02	0.10	0.18	0.07	0.03	0.00	0.00
Operating Cost of Revenue	0.03	0.05	0.03	0.03	0.02	0.10	0.18	0.07	0.03	0.00	0.00
Total Operating Expenses	1.97	1.27	1.96	7.02	4.36	4.36	4.71	6.80	6.73	6.21	13
Selling, General & Admin Expense	0.08	0.23	0.20	0.30	0.37	3.98	4.97	4.96	3.06	3.85	4.35
Research & Development Expense	0.15	0.01	0.05	0.49	0.56	0.39	1.26	1.84	3.67	2.36	8.24
Total Other Income / (Expense), net	0.00	-0.00	-0.01	0.00	0.00	0.00	0.00	-0.76	-0.14	-0.06	-0.03
Interest & Investment Income	-	-	-	-	-	-	-	-	-	0.01	0.00
Other Income / (Expense), net	-	-	-	-	-	-	-	-0.76	-0.18	-0.07	-0.03
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.16	-0.06	-0.06	-	-0.06	-0.15	-0.16	-0.11	-0.05	-0.01	-0.01
Weighted Average Basic Shares Outstanding	39.70M	43.84M	58.77M	70.96M	77.79M	2.77M	5.73M	5.89M	6.61M	17.45M	22.23M
Diluted Earnings per Share	($0.04)	($0.03)	($0.03)	($0.09)	($0.05)	($1.47)	($0.95)	($1.24)	($1.01)	($0.47)	($0.66)
Weighted Average Diluted Shares Outstanding	39.70M	43.84M	58.77M	70.96M	77.79M	2.77M	5.73M	5.89M	6.61M	12.38M	18.00M
Weighted Average Basic & Diluted Shares Outstanding	39.70M	43.84M	58.77M	70.96M	77.79M	2.77M	4.39M	5.89M	6.61M	17.45M	22.23M

This table shows Lexaria Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	11/30/2023	2/29/2024	5/31/2024	8/31/2024	11/30/2024	2/28/2025	5/31/2025	8/31/2025	11/30/2025	2/28/2026	5/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-1.18	-0.65	-1.78	-2.18	-2.70	-2.71	-3.79	-2.70	-1.60	-1.45	-1.99
Consolidated Net Income / (Loss)	-1.19	-0.65	-1.78	-2.19	-2.71	-2.72	-3.79	-2.70	-1.60	-1.45	-1.99
Net Income / (Loss) Continuing Operations	-1.19	-0.65	-1.78	-2.19	-2.71	-2.72	-3.79	-2.70	-1.60	-1.45	-1.99
Total Pre-Tax Income	-1.19	-0.65	-1.78	-2.19	-2.71	-2.72	-3.79	-2.70	-1.60	-1.45	-1.99
Total Operating Income	-1.14	-0.67	-1.74	-2.20	-2.69	-2.75	-3.75	-2.69	-1.57	-1.45	-1.99
Total Gross Profit	0.15	0.15	0.08	0.08	0.18	0.17	0.17	0.17	0.00	0.02	0.00
Total Revenue	0.15	0.15	0.08	0.08	0.18	0.17	0.17	0.17	0.00	0.02	0.00
Operating Revenue	0.15	0.15	0.08	0.08	0.18	0.17	0.17	0.17	0.00	0.02	0.00
Total Cost of Revenue	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00
Operating Cost of Revenue	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Operating Expenses	1.29	0.81	1.83	2.29	2.87	2.93	3.92	2.85	1.57	1.47	1.99
Selling, General & Admin Expense	0.71	0.57	1.25	1.32	0.92	1.24	1.21	0.98	0.90	1.00	1.02
Research & Development Expense	0.57	0.25	0.57	0.97	1.95	1.69	2.72	1.88	0.67	0.48	0.97
Other Operating Expenses / (Income)	-	-	-	-	-	-	-	-	-	-	0.00
Total Other Income / (Expense), net	-0.05	0.02	-0.04	0.02	-0.02	0.03	-0.04	-0.01	-0.02	0.00	0.00
Interest & Investment Income	0.01	-0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Tax Expense	-	-	-	-	0.00	0.00	0.00	-	0.00	0.00	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.01	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
Weighted Average Basic Shares Outstanding	-	10.77M	13.86M	17.45M	17.55M	17.56M	19.56M	22.23M	24.89M	24.79M	24.79M
Diluted Earnings per Share	($0.13)	($0.06)	($0.13)	($0.15)	($0.16)	($0.15)	($0.21)	($0.14)	($0.07)	($0.06)	($0.08)
Weighted Average Diluted Shares Outstanding	9.05M	10.77M	13.86M	12.38M	16.67M	17.51M	18.30M	18.00M	21.38M	24.44M	24.81M
Weighted Average Basic & Diluted Shares Outstanding	-	10.77M	13.86M	17.45M	17.55M	17.56M	19.56M	22.23M	24.89M	24.79M	24.79M

This table details how cash moves in and out of Lexaria Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	8/31/2015	8/31/2016	8/31/2017	8/31/2018	8/31/2019	8/31/2020	8/31/2021	8/31/2022	8/31/2023	8/31/2024	8/31/2025
Net Change in Cash & Equivalents	-0.44	-0.17	2.44	-0.81	-0.44	0.01	9.62	-6.30	-4.46	5.15	-4.70
Net Cash From Operating Activities	-1.50	-0.66	-1.55	-2.52	-3.01	-2.62	-3.99	-4.88	-5.88	-4.96	-10
Net Cash From Continuing Operating Activities	-1.60	-0.66	-1.55	-2.52	-3.01	-2.32	-1.62	-6.08	-5.88	-4.96	-10
Net Income / (Loss) Continuing Operations	-1.93	-1.28	-1.93	-6.61	-4.16	-4.08	-4.19	-7.38	0.00	0.00	0.00
Depreciation Expense	0.00	0.00	0.00	0.00	0.06	0.11	0.11	0.10	0.15	0.08	0.09
Non-Cash Adjustments To Reconcile Net Income	0.50	0.54	0.44	4.43	1.05	1.46	-0.08	0.76	-6.17	-5.14	-11
Changes in Operating Assets and Liabilities, net	-0.07	0.08	-0.06	-0.34	0.04	0.19	0.12	0.44	0.14	0.11	0.20
Net Cash From Investing Activities	0.68	-0.02	-0.01	-0.16	-0.77	-0.03	0.19	-0.18	-0.17	-0.19	-0.24
Net Cash From Continuing Investing Activities	0.68	-0.02	-0.01	-0.16	-0.77	-0.03	0.19	-0.18	-0.17	-0.19	-0.24
Purchase of Property, Plant & Equipment	0.00	-0.00	0.00	0.00	-0.65	-	-	-0.05	-0.03	-0.04	-0.02
Acquisitions	-0.04	-0.02	-0.01	-0.09	-0.12	-0.03	-0.08	-0.13	-0.14	-0.15	-0.08
Sale and/or Maturity of Investments	0.00	-	-	-	0.00	0.01	0.00	-	-	0.00	-0.14
Net Cash From Financing Activities	0.37	0.51	4.00	1.87	3.33	2.65	13	-0.04	1.59	10	6.05
Net Cash From Continuing Financing Activities	0.37	0.51	4.00	1.87	3.33	2.67	13	-0.04	1.59	10	6.05
Issuance of Common Equity	-	0.42	4.05	1.87	3.33	2.67	9.47	0.00	1.59	4.21	6.05
Other Financing Activities, net	0.47	0.10	-0.05	-	-	0.00	4.02	-0.04	0.00	6.11	0.00
Effect of Exchange Rate Changes	-	-	-	-	-	-	-	-	0.00	-0.02	-0.05

This table details how cash moves in and out of Lexaria Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	11/30/2023	2/29/2024	5/31/2024	8/31/2024	11/30/2024	2/28/2025	5/31/2025	8/31/2025	11/30/2025	2/28/2026	5/31/2026
Net Change in Cash & Equivalents	0.60	2.75	3.75	-1.96	1.58	-1.61	-1.88	-2.79	2.48	0.85	-1.65
Net Cash From Operating Activities	-1.18	-0.62	-1.27	-1.89	-2.73	-1.50	-3.58	-2.64	-0.98	-2.16	-1.64
Net Cash From Continuing Operating Activities	-1.18	-0.62	-1.27	-1.89	-2.73	-1.50	-3.58	-2.64	-0.98	-2.14	-1.66
Net Income / (Loss) Continuing Operations	-1.19	-0.65	-1.78	3.62	0.00	-5.42	-3.79	9.21	0.00	-3.05	-1.99
Consolidated Net Income / (Loss)	-1.19	-0.65	-1.78	-	-	-	-3.79	-	-	-	-1.99
Depreciation Expense	0.03	0.02	0.02	0.02	0.03	0.00	0.03	0.02	0.02	0.02	0.02
Non-Cash Adjustments To Reconcile Net Income	0.11	0.03	0.43	-5.70	-2.58	2.88	0.52	-12	-1.49	1.68	0.10
Changes in Operating Assets and Liabilities, net	-0.13	-0.01	0.08	0.17	-0.18	1.04	-0.34	-0.32	0.49	-0.81	0.24
Net Cash From Investing Activities	-0.04	-0.06	-0.02	-0.07	-0.04	-0.03	-0.02	-0.16	-0.01	-0.05	-0.03
Net Cash From Continuing Investing Activities	-0.04	-0.06	-0.02	-0.07	-0.04	-0.03	-0.02	-0.16	-0.01	-0.05	-0.03
Acquisitions	-	-	-	-0.03	-0.01	-0.03	-0.02	-0.01	-0.01	-0.02	-0.03
Sale and/or Maturity of Investments	-	-	-	-	-	-	-	-	-	-	-0.00
Effect of Exchange Rate Changes	0.00	-0.02	-0.00	0.00	-0.00	-0.10	0.04	0.01	-0.01	0.02	0.01
Cash Income Taxes Paid	0.00	-	-	-	0.00	-	-	-	0.00	0.00	0.00

This table presents Lexaria Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	8/31/2015	8/31/2016	8/31/2017	8/31/2018	8/31/2019	8/31/2020	8/31/2021	8/31/2022	8/31/2023	8/31/2024	8/31/2025
Total Assets	0.71	0.57	2.86	2.43	2.68	2.83	13	7.83	3.08	8.87	4.18
Total Current Assets	0.67	0.51	2.80	2.28	1.82	1.93	12	6.98	2.15	7.90	3.47
Cash & Equivalents	0.26	0.09	2.53	1.73	1.29	1.29	11	5.81	1.35	6.50	1.80
Short-Term Investments	-	-	0.00	0.01	0.06	0.02	0.83	0.35	0.13	0.06	0.17
Accounts Receivable	0.03	0.13	0.05	0.27	0.27	0.31	0.34	0.20	0.13	0.15	0.37
Prepaid Expenses	0.22	0.15	0.15	0.19	0.07	0.18	0.32	0.58	0.55	1.19	1.13
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.59	0.00	0.37	0.32	0.25	0.25	0.23
Total Noncurrent Assets	0.04	0.05	0.06	0.15	0.27	0.29	0.46	0.54	0.68	0.72	0.48
Long-Term Investments	-	-	-	-	-	-	-	-	0.05	0.06	0.06
Intangible Assets	-	-	-	-	-	-	-	-	-	0.52	0.31
Other Noncurrent Operating Assets	0.04	0.05	0.06	0.15	0.27	0.29	0.46	0.49	0.63	0.13	0.11
Total Liabilities & Shareholders' Equity	0.71	0.57	2.86	2.43	2.68	2.83	13	7.83	3.08	8.87	4.18
Total Liabilities	0.06	0.48	0.09	0.04	0.18	0.35	0.20	0.20	0.40	1.21	1.57
Total Current Liabilities	0.06	0.43	0.09	0.04	0.18	0.23	0.15	0.19	0.27	1.10	1.49
Accounts Payable	0.06	0.42	0.08	0.04	0.18	0.15	0.11	0.15	0.24	1.07	1.46
Other Current Liabilities	0.00	0.00	-	-	0.00	0.04	0.04	0.04	0.03	0.03	0.03
Total Noncurrent Liabilities	0.00	0.05	0.00	0.00	0.00	0.12	0.05	0.01	0.14	0.11	0.08
Other Noncurrent Operating Liabilities	-	-	-	-	0.00	0.09	0.05	0.01	0.14	0.11	0.08
Total Equity & Noncontrolling Interests	0.66	0.09	2.77	2.39	2.49	2.48	13	7.63	2.68	7.66	2.60
Total Preferred & Common Equity	0.77	0.27	3.01	2.39	2.38	2.48	13	7.95	3.04	8.04	2.99
Total Common Equity	0.77	0.27	3.01	2.39	2.38	2.48	13	7.95	3.04	8.04	2.99
Common Stock	11	12	16	22	26	30	45	47	49	60	67
Retained Earnings	-10	-11	-13	-20	-24	-28	-32	-39	-46	-52	-63
Accumulated Other Comprehensive Income / (Loss)	-	-	0.00	-0.01	0.00	-	-	-	0.00	-0.02	-0.07
Noncontrolling Interest	-0.12	-0.18	-0.24	0.00	0.11	-	-0.20	-0.32	-0.36	-0.38	-0.39

This table presents Lexaria Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	11/30/2023	2/29/2024	5/31/2024	11/30/2024	2/28/2025	5/31/2025	11/30/2025	2/28/2026	5/31/2026
Total Assets	3.63	6.35	10	9.79	8.68	6.74	6.05	6.49	4.78
Total Current Assets	2.69	5.42	9.09	8.83	7.72	5.81	5.36	5.77	4.06
Cash & Equivalents	1.95	4.71	8.46	8.08	6.47	4.59	4.28	5.13	3.48
Short-Term Investments	0.07	0.09	0.05	0.04	0.07	0.03	0.14	0.14	0.14
Accounts Receivable	0.53	0.36	0.21	0.26	0.33	0.36	0.09	0.04	0.05
Prepaid Expenses	0.13	0.27	0.38	0.44	0.85	0.82	0.85	0.46	0.40
Plant, Property, & Equipment, net	0.23	0.23	0.22	0.27	0.26	0.24	0.22	0.24	0.23
Total Noncurrent Assets	0.70	0.71	0.71	0.70	0.69	0.69	0.47	0.47	0.49
Long-Term Investments	-	-	-	0.06	0.06	0.06	0.06	0.06	0.06
Intangible Assets	-	-	-	0.51	0.51	0.52	0.31	0.32	0.34
Other Noncurrent Operating Assets	0.65	0.67	0.64	0.13	0.12	0.11	0.10	0.09	0.08
Total Liabilities & Shareholders' Equity	3.63	6.35	10	9.79	8.68	6.74	6.05	6.49	4.78
Total Liabilities	0.25	0.20	0.27	0.40	1.92	1.57	1.53	0.28	0.44
Total Current Liabilities	0.12	0.08	0.16	0.30	1.82	1.49	1.46	0.21	0.38
Accounts Payable	0.10	0.06	0.13	0.27	1.79	1.46	1.43	0.18	0.35
Other Current Liabilities	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Total Noncurrent Liabilities	0.13	0.12	0.12	0.10	0.09	0.09	0.07	0.06	0.05
Other Noncurrent Operating Liabilities	0.13	0.12	0.12	0.10	0.09	0.09	0.07	0.06	0.05
Total Equity & Noncontrolling Interests	3.37	6.15	9.75	9.39	6.76	5.17	4.52	6.21	4.34
Total Preferred & Common Equity	3.74	6.52	10	9.77	7.14	5.55	4.91	6.60	4.74
Total Common Equity	3.74	6.52	10	9.77	7.14	5.55	4.91	6.60	4.74
Common Stock	51	54	60	64	64	66	70	73	73
Retained Earnings	-47	-48	-49	-54	-57	-61	-65	-67	-68
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.02	-0.02	-0.02	-0.12	-0.08	-0.08	-0.06	-0.05
Noncontrolling Interest	-0.37	-0.37	-0.38	-0.38	-0.38	-0.39	-0.39	-0.39	-0.39

This table displays calculated financial ratios and metrics derived from Lexaria Bioscience's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	8/31/2015	8/31/2016	8/31/2017	8/31/2018	8/31/2019	8/31/2020	8/31/2021	8/31/2022	8/31/2023	8/31/2024	8/31/2025
DEI Shares Outstanding	79,785,968.00	45,513,282.00	66,972,303.00	73,144,805.00	78,637,134.00	89,587,090.00	5,104,332.00	5,950,998.00	8,091,650.00	15,810,205.00	19,559,179.00
DEI Adjusted Shares Outstanding	2,659,532.00	1,517,109.00	2,232,410.00	2,438,160.00	2,621,238.00	2,986,236.00	5,104,332.00	5,950,998.00	8,091,650.00	15,810,205.00	19,559,179.00
DEI Earnings Per Adjusted Shares Outstanding	-0.67	-0.80	-0.84	-2.71	-1.56	-1.32	-0.79	-1.22	-0.82	-0.37	-0.61
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	176.96%	56.29%	580.85%	-48.62%	41.41%	129.59%	-64.66%	-11.43%	105.24%	52.05%
EBITDA Growth	-154.37%	67.87%	-50.82%	-243.76%	37.98%	1.51%	-0.41%	-79.67%	9.80%	12.49%	-105.79%
EBIT Growth	-154.37%	67.86%	-50.86%	-243.61%	37.08%	0.23%	-0.37%	-77.31%	9.09%	13.25%	-104.61%
NOPAT Growth	-154.37%	67.86%	-50.86%	-243.61%	37.08%	0.23%	-0.37%	-58.95%	1.28%	11.95%	-106.51%
Net Income Growth	40.62%	33.97%	-51.06%	-242.54%	37.08%	1.77%	-2.49%	-76.38%	9.09%	13.47%	-105.06%
EPS Growth	71.43%	25.00%	0.00%	-200.00%	44.44%	-2,840.00%	35.37%	-30.53%	18.55%	53.47%	-40.43%
Operating Cash Flow Growth	-191.00%	55.97%	-133.93%	-62.88%	-19.36%	12.87%	-52.35%	-22.30%	-20.53%	15.68%	-110.74%
Free Cash Flow Firm Growth	-542.50%	97.86%	-1,010.61%	-227.12%	32.55%	30.84%	-54.96%	-31.28%	11.07%	8.05%	-100.55%
Invested Capital Growth	45.26%	-95.04%	495.95%	177.56%	75.36%	-48.34%	123.86%	11.52%	-21.62%	-9.88%	-45.06%
Revenue Q/Q Growth	223.38%	10.68%	6.70%	23.98%	0.00%	0.00%	-24.61%	45.72%	-26.22%	12.96%	14.61%
EBITDA Q/Q Growth	-155.39%	18.46%	45.52%	-8.35%	-3,969.78%	-3,766.80%	34.65%	-31.32%	-8.20%	-21.43%	-4.56%
EBIT Q/Q Growth	-155.39%	18.42%	51.84%	-8.36%	0.00%	0.00%	34.04%	-30.67%	-8.82%	-19.73%	-4.57%
NOPAT Q/Q Growth	-150.59%	18.42%	32.67%	-8.36%	0.00%	0.00%	34.04%	-17.14%	-5.93%	-23.35%	-4.26%
Net Income Q/Q Growth	100.44%	18.33%	-25.30%	-8.34%	0.00%	0.00%	12.30%	-2.93%	3.79%	-19.25%	-4.48%
EPS Q/Q Growth	133.33%	25.00%	0.00%	-12.50%	0.00%	0.00%	-4.40%	0.00%	0.00%	-6.82%	1.49%
Operating Cash Flow Q/Q Growth	-126.26%	0.00%	-6.37%	-23.78%	3.23%	3.58%	-13.45%	-1.34%	-8.19%	-5.76%	-7.74%
Free Cash Flow Firm Q/Q Growth	-726.68%	86.86%	76.63%	-41.47%	59.91%	-161.27%	27.20%	-26.85%	-27.26%	-0.37%	-8.82%
Invested Capital Q/Q Growth	0.00%	205.25%	-81.41%	16.96%	-77.25%	-49.91%	-25.20%	-6.93%	89.87%	-16.26%	19.71%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	-206.52%	-12.03%	53.25%	94.19%	89.72%	68.43%	75.74%	71.87%	86.07%	98.96%	99.61%
EBITDA Margin	-26,979.59%	-3,129.77%	-3,020.10%	-1,524.83%	-1,840.83%	-1,282.13%	-560.71%	-2,850.83%	-2,903.14%	-1,237.80%	-1,675.34%
Operating Margin	-26,979.59%	-3,131.29%	-3,022.44%	-1,525.36%	-1,868.03%	-1,317.94%	-576.16%	-2,591.67%	-2,888.50%	-1,239.16%	-1,683.01%
EBIT Margin	-26,979.59%	-3,131.29%	-3,022.44%	-1,525.36%	-1,868.03%	-1,317.94%	-576.16%	-2,891.05%	-2,967.41%	-1,254.20%	-1,687.78%
Profit (Net Income) Margin	-26,314.13%	-3,136.82%	-3,031.89%	-1,525.36%	-1,868.03%	-1,297.56%	-579.21%	-2,891.05%	-2,967.41%	-1,251.12%	-1,687.36%
Tax Burden Percent	195.07%	100.00%	100.00%	100.00%	100.00%	98.45%	100.53%	100.00%	100.65%	100.00%	100.00%
Interest Burden Percent	100.00%	100.18%	100.31%	100.00%	100.00%	100.00%	100.00%	100.00%	99.36%	99.75%	99.97%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-385.71%	-214.44%	-983.35%	-1,045.11%	-324.84%	-335.56%	-305.32%	-331.93%	-348.39%	-367.18%	-1,032.44%
ROIC Less NNEP Spread (ROIC-NNEP)	-639.35%	-79.10%	-938.18%	-952.26%	-244.01%	-262.74%	-286.67%	-301.20%	-292.74%	-323.44%	-949.33%
Return on Net Nonoperating Assets (RNNOA)	610.76%	60.42%	848.22%	788.75%	154.37%	171.29%	251.46%	260.57%	218.21%	254.82%	800.29%
Return on Equity (ROE)	-325.96%	-154.02%	-135.14%	-256.37%	-170.47%	-164.27%	-53.86%	-71.35%	-130.18%	-112.36%	-232.15%
Cash Return on Invested Capital (CROIC)	-1,803.83%	-33.35%	-1,125.88%	-1,139.17%	-379.58%	-271.81%	-381.81%	-342.82%	-324.15%	-356.79%	-974.27%
Operating Return on Assets (OROA)	-237.03%	-199.47%	-112.26%	-249.78%	-162.85%	-150.77%	-51.74%	-69.98%	-122.96%	-97.44%	-182.70%
Return on Assets (ROA)	-231.18%	-199.83%	-112.61%	-249.78%	-162.85%	-148.44%	-52.02%	-69.98%	-122.96%	-97.20%	-182.65%
Return on Common Equity (ROCE)	-341.87%	-214.88%	-154.86%	-268.23%	-166.70%	-160.72%	-54.56%	-73.14%	-138.77%	-120.42%	-249.44%
Return on Equity Simple (ROE_SIMPLE)	-250.43%	-480.09%	-64.18%	-276.75%	-174.50%	-164.55%	-31.56%	-92.89%	-220.51%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-2.78	-0.89	-1.35	-4.63	-2.91	-2.90	-2.91	-4.63	-4.57	-4.03	-8.32
NOPAT Margin	-9,442.86%	-2,191.90%	-2,115.71%	-1,067.75%	-1,307.62%	-922.56%	-403.31%	-1,814.17%	-2,021.95%	-867.41%	-1,178.11%
Net Nonoperating Expense Percent (NNEP)	-60.12%	-135.34%	-45.17%	-92.85%	-80.83%	-72.82%	-18.64%	-30.72%	-55.65%	-43.74%	-83.11%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-52.58%	-319.53%
Cost of Revenue to Revenue	406.52%	112.03%	46.75%	5.81%	10.28%	31.57%	24.26%	28.13%	13.93%	1.04%	0.39%
SG&A Expenses to Revenue	556.05%	563.88%	320.26%	69.98%	168.28%	1,263.41%	687.85%	1,942.04%	1,353.63%	829.68%	615.53%
R&D to Revenue	1,992.46%	22.16%	85.14%	113.75%	249.64%	122.96%	174.74%	721.49%	1,620.95%	508.44%	1,167.09%
Operating Expenses to Revenue	26,773.08%	3,119.26%	3,075.69%	1,619.55%	1,957.74%	1,386.38%	651.90%	2,663.54%	2,974.58%	1,338.12%	1,782.62%
Earnings before Interest and Taxes (EBIT)	-3.97	-1.27	-1.92	-6.61	-4.16	-4.15	-4.16	-7.38	-6.71	-5.82	-12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3.97	-1.27	-1.92	-6.61	-4.10	-4.04	-4.05	-7.28	-6.57	-5.75	-12
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	13.36	44.21	5.76	35.53	22.77	10.11	2.39	2.22	2.79	7.69	5.76
Price to Tangible Book Value (P/TBV)	13.36	44.21	5.76	35.53	22.77	10.11	2.39	2.22	2.79	8.22	6.42
Price to Revenue (P/Rev)	701.86	288.83	271.93	195.82	243.74	79.69	43.93	68.97	37.56	133.15	24.39
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	25.08	293.13	61.98	127.70	46.45	40.37	15.00	7.57	5.72	52.72	25.91
Enterprise Value to Revenue (EV/Rev)	676.29	283.26	228.38	191.81	238.17	75.61	27.40	43.61	29.20	118.08	20.96
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.51	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.51	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.39	-0.76	-0.90	-0.83	-0.63	-0.65	-0.88	-0.87	-0.75	-0.79	-0.84
Leverage Ratio	2.82	1.72	1.20	1.03	1.05	1.11	1.04	1.02	1.06	1.16	1.27
Compound Leverage Factor	2.82	1.72	1.20	1.03	1.05	1.11	1.04	1.02	1.05	1.15	1.27
Debt to Total Capital	0.00%	33.90%	0.00%	0.00%	0.00%	1.22%	0.06%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	33.90%	0.00%	0.00%	0.00%	1.22%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-35.28%	-134.30%	-8.62%	0.00%	4.32%	0.00%	-1.55%	-4.15%	-13.58%	-4.93%	-14.87%
Common Equity to Total Capital	235.28%	200.40%	108.62%	100.00%	95.68%	98.78%	101.49%	104.15%	113.58%	104.93%	114.87%
Debt to EBITDA	0.00	-0.04	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.04	0.00	0.00	0.00	0.32	2.90	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.04	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.05	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.05	0.00	0.00	0.00	0.44	4.03	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.05	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	168.03	-20.38	104.93	1,147.50	159.64	25.73	90.49	43.44	-14.53	21.35	-23.39
Noncontrolling Interest Sharing Ratio	-9.76%	-39.51%	-14.59%	-4.63%	2.21%	2.17%	-1.30%	-2.51%	-6.60%	-7.17%	-7.45%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	24.48	1.18	30.27	52.34	9.86	8.53	81.18	35.96	8.03	7.18	2.32
Quick Ratio	5.29	0.52	27.92	45.90	8.79	7.20	78.90	32.79	5.99	6.10	1.56
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.49	-0.14	-1.54	-5.04	-3.40	-2.35	-3.65	-4.79	-4.26	-3.91	-7.85
Operating Cash Flow to CapEx	0.00%	-21,359.28%	0.00%	0.00%	-465.12%	0.00%	0.00%	-9,918.97%	-17,426.92%	-11,528.81%	-42,401.96%
Free Cash Flow to Firm to Interest Expense	0.00	-61.69	-256.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-293.71	-257.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-295.09	-257.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.06	0.04	0.16	0.09	0.11	0.09	0.02	0.04	0.08	0.11
Accounts Receivable Turnover	0.46	0.50	0.72	2.79	0.83	1.07	2.20	0.94	1.38	3.30	2.70
Inventory Turnover	0.00	0.30	0.29	0.33	0.21	0.81	2.39	2.11	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	29.39	280.17	0.75	0.00	0.00	0.75	0.79	1.82	2.92
Accounts Payable Turnover	0.79	0.19	0.12	0.42	0.20	0.60	1.39	0.56	0.16	0.01	0.00
Days Sales Outstanding (DSO)	3,187.36	728.18	505.80	131.01	441.80	340.35	165.73	388.86	265.00	110.52	135.17
Days Inventory Outstanding (DIO)	0.00	1,211.11	1,238.53	1,118.89	1,710.99	448.58	152.50	172.91	0.00	0.00	0.00
Days Payable Outstanding (DPO)	1,837.61	1,906.44	3,046.65	861.62	1,818.76	606.26	261.83	653.87	2,267.58	49,441.91	169,715.27
Cash Conversion Cycle (CCC)	1,349.75	32.84	-1,302.31	388.28	334.03	182.67	56.39	-92.10	-2,002.57	-49,331.39	-169,580.10
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.79	0.04	0.23	0.65	1.14	0.59	1.32	1.47	1.15	1.04	0.57
Invested Capital Turnover	0.04	0.10	0.46	0.98	0.25	0.36	0.76	0.18	0.17	0.42	0.88
Increase / (Decrease) in Invested Capital	0.94	-0.75	0.20	0.42	0.49	-0.55	0.73	0.15	-0.32	-0.11	-0.47
Enterprise Value (EV)	9.94	12	15	83	53	24	20	11	6.61	55	15
Market Capitalization	10	12	17	85	54	25	32	18	8.50	62	17
Book Value per Share	$0.04	$0.01	$0.04	$0.03	$0.03	$0.03	$2.60	$1.34	$0.38	$0.51	$0.15
Tangible Book Value per Share	$0.04	$0.01	$0.04	$0.03	$0.03	$0.03	$2.60	$1.34	$0.38	$0.48	$0.14
Total Capital	1.31	0.13	2.77	2.39	2.49	2.51	13	7.63	2.68	7.66	2.60
Total Debt	0.00	0.05	0.00	0.00	0.00	0.03	0.01	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.05	0.00	0.00	0.00	0.03	0.00	0.00	0.00	0.00	0.00
Net Debt	-0.52	-0.05	-2.53	-1.74	-1.35	-1.28	-12	-6.16	-1.53	-6.62	-2.03
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.65	0.00	0.00	0.05	0.03	0.04	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.72	-0.02	0.17	0.50	0.28	0.39	0.55	0.62	0.41	0.24	0.01
Debt-free Net Working Capital (DFNWC)	1.24	0.08	2.70	2.24	1.63	1.70	12	6.78	1.88	6.80	1.97
Net Working Capital (NWC)	1.24	0.08	2.70	2.24	1.63	1.70	12	6.78	1.88	6.80	1.97
Net Nonoperating Expense (NNE)	1.09	0.38	0.58	1.98	1.25	1.18	1.27	2.75	2.14	1.78	3.59
Net Nonoperating Obligations (NNO)	-0.52	-0.05	-2.53	-1.74	-1.35	-1.89	-12	-6.16	-1.53	-6.62	-2.03
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.06	0.11	0.11	0.10	0.15	0.08	0.09
Debt-free, Cash-free Net Working Capital to Revenue	4,890.94%	-42.06%	266.83%	116.11%	128.01%	122.93%	75.54%	243.91%	179.36%	52.31%	1.05%
Debt-free Net Working Capital to Revenue	8,428.89%	187.35%	4,247.63%	517.07%	734.16%	540.05%	1,701.53%	2,656.05%	832.63%	1,464.33%	279.76%
Net Working Capital to Revenue	8,428.89%	187.35%	4,247.63%	517.07%	734.16%	540.05%	1,700.43%	2,656.05%	832.63%	1,464.33%	279.76%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.50)	($0.90)	($0.90)	($2.70)	($1.50)	($1.50)	($0.95)	$0.00	($1.01)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	1.33M	1.75M	2.31M	2.57M	2.63M	3.00M	5.73M	0.00	10.28M	17.45M	22.23M
Adjusted Diluted Earnings per Share	($1.50)	($0.90)	($0.90)	($2.70)	($1.50)	($1.50)	($0.95)	$0.00	($1.01)	($0.47)	($0.66)
Adjusted Weighted Average Diluted Shares Outstanding	1.33M	1.75M	2.31M	2.57M	2.63M	3.00M	5.73M	0.00	10.28M	12.38M	18.00M
Adjusted Basic & Diluted Earnings per Share	($1.50)	($0.90)	($0.90)	($2.70)	($1.50)	($1.50)	($0.95)	$0.00	($1.01)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.20M	1.46M	1.96M	2.37M	2.59M	2.77M	4.39M	0.00	6.61M	17.45M	22.23M
Normalized Net Operating Profit after Tax (NOPAT)	-2.35	-0.87	-1.25	-4.43	-2.44	-2.90	-3.98	-4.63	-4.57	-4.03	-8.32
Normalized NOPAT Margin	-16,010.12%	-2,126.68%	-1,965.88%	-1,021.70%	-1,096.66%	-922.56%	-550.79%	-1,814.17%	-2,021.95%	-867.41%	-1,178.11%
Pre Tax Income Margin	-26,979.59%	-3,136.82%	-3,031.89%	-1,525.36%	-1,868.03%	-1,317.94%	-576.16%	-2,891.05%	-2,948.32%	-1,251.12%	-1,687.36%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-566.67	-319.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-396.67	-223.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-568.04	-319.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-398.04	-223.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Lexaria Bioscience's official financial filings.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	11/30/2023	2/29/2024	5/31/2024	8/31/2024	11/30/2024	2/28/2025	5/31/2025	8/31/2025	11/30/2025	2/28/2026	5/31/2026
DEI Shares Outstanding	8,091,650.00	10,435,441.00	12,885,673.00	15,810,205.00	17,452,594.00	17,552,594.00	17,559,179.00	19,559,179.00	22,225,846.00	24,887,446.00	24,787,446.00
DEI Adjusted Shares Outstanding	8,091,650.00	10,435,441.00	12,885,673.00	15,810,205.00	17,452,594.00	17,552,594.00	17,559,179.00	19,559,179.00	22,225,846.00	24,887,446.00	24,787,446.00
DEI Earnings Per Adjusted Shares Outstanding	-0.15	-0.06	-0.14	-0.14	-0.15	-0.15	-0.22	-0.14	-0.07	-0.06	-0.08
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	54.78%	624.09%	8.10%	468.39%	21.58%	20.00%	107.14%	107.14%	-100.00%	-88.51%	-100.00%
EBITDA Growth	33.30%	51.20%	24.99%	-24.60%	-129.76%	-326.30%	-112.51%	-23.03%	40.94%	47.22%	47.48%
EBIT Growth	32.61%	50.76%	25.14%	-20.64%	-127.00%	-316.25%	-112.45%	-23.09%	41.04%	46.56%	47.40%
NOPAT Growth	32.81%	49.53%	27.40%	-31.89%	-136.20%	-311.83%	-115.18%	-22.04%	41.52%	47.22%	46.84%
Net Income Growth	33.02%	50.20%	25.14%	-19.27%	-128.40%	-316.25%	-112.44%	-23.35%	40.98%	46.53%	47.42%
EPS Growth	56.67%	72.73%	64.86%	48.28%	-23.08%	-150.00%	-61.54%	6.67%	56.25%	60.00%	61.90%
Operating Cash Flow Growth	5.11%	52.04%	29.11%	-16.65%	-130.70%	-141.75%	-183.08%	-39.69%	63.90%	-44.46%	54.38%
Free Cash Flow Firm Growth	135.72%	-345.44%	-162.35%	-67.80%	-664.09%	0.74%	-0.37%	1.03%	102.44%	-139.95%	15.01%
Invested Capital Growth	0.00%	24.06%	104.33%	-9.88%	0.00%	-88.64%	-61.57%	-45.06%	-97.12%	469.76%	38.96%
Revenue Q/Q Growth	763.44%	-4.15%	-42.07%	0.00%	118.96%	-5.40%	0.00%	0.00%	-100.00%	0.00%	-100.00%
EBITDA Q/Q Growth	33.41%	45.27%	-177.83%	-23.06%	-22.79%	-1.54%	-38.50%	28.76%	41.06%	9.25%	-37.81%
EBIT Q/Q Growth	34.42%	45.26%	-173.36%	-22.94%	-23.39%	-0.38%	-39.52%	28.77%	40.90%	9.01%	-37.32%
NOPAT Q/Q Growth	31.80%	41.36%	-160.91%	-26.40%	-22.13%	-2.24%	-36.33%	28.31%	41.47%	7.74%	-37.32%
Net Income Q/Q Growth	35.36%	44.92%	-173.36%	-22.54%	-23.78%	-0.38%	-39.52%	28.84%	40.77%	9.06%	-37.19%
EPS Q/Q Growth	55.17%	53.85%	-116.67%	-15.38%	-6.67%	6.25%	-40.00%	33.33%	50.00%	14.29%	-33.33%
Operating Cash Flow Q/Q Growth	27.13%	47.56%	-104.33%	-49.41%	-44.11%	45.05%	-139.27%	26.27%	62.76%	-119.88%	24.44%
Free Cash Flow Firm Q/Q Growth	164.47%	-233.09%	-153.87%	22.97%	-116.74%	76.58%	-156.71%	24.04%	105.34%	-2,405.85%	9.07%
Invested Capital Q/Q Growth	-100.00%	0.00%	-8.35%	-16.26%	16.55%	-87.30%	210.07%	19.71%	-93.88%	2,409.62%	-24.38%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	96.81%	100.00%	100.00%	100.00%	98.52%	100.00%	100.00%	100.00%	0.00%	100.00%	0.00%
EBITDA Margin	-769.17%	-439.17%	-2,106.24%	-2,591.90%	-1,453.57%	-1,560.17%	-2,160.83%	-1,539.46%	0.00%	-7,164.01%	0.00%
Operating Margin	-753.01%	-460.69%	-2,074.90%	-2,622.70%	-1,462.95%	-1,581.04%	-2,155.41%	-1,545.17%	0.00%	-7,259.52%	0.00%
EBIT Margin	-788.19%	-450.16%	-2,124.18%	-2,611.39%	-1,471.62%	-1,561.48%	-2,178.62%	-1,551.76%	0.00%	-7,259.52%	0.00%
Profit (Net Income) Margin	-783.35%	-450.16%	-2,124.18%	-2,603.06%	-1,471.61%	-1,561.48%	-2,178.51%	-1,550.13%	0.00%	-7,263.66%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.11%	100.18%	100.00%
Interest Burden Percent	99.39%	100.00%	100.00%	99.68%	100.00%	100.00%	100.00%	99.90%	100.00%	99.88%	99.96%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-92.57%	-645.61%	-777.15%	-839.80%	-771.62%	-1,081.28%	-947.88%	0.00%	-3,628.38%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-88.13%	-636.15%	-761.33%	-819.68%	-757.74%	-1,063.62%	-929.04%	0.00%	-3,621.07%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	68.12%	550.83%	599.80%	713.93%	669.18%	941.03%	783.18%	0.00%	3,333.31%	0.00%
Return on Equity (ROE)	0.00%	-24.45%	-94.78%	-177.35%	-125.87%	-102.44%	-140.25%	-164.70%	0.00%	-295.07%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	-357.82%	-421.65%	-356.79%	-1,043.84%	-711.97%	-839.17%	-974.27%	-1,019.78%	-1,425.73%	-978.93%
Operating Return on Assets (OROA)	0.00%	-28.21%	-114.44%	-202.88%	-74.67%	-109.28%	-160.13%	-167.97%	0.00%	-352.33%	0.00%
Return on Assets (ROA)	0.00%	-28.21%	-114.44%	-202.24%	-74.67%	-109.28%	-160.12%	-167.80%	0.00%	-352.53%	0.00%
Return on Common Equity (ROCE)	0.00%	-26.07%	-99.79%	-190.06%	-130.96%	-108.45%	-147.41%	-176.97%	0.00%	-312.73%	0.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-92.85%	-48.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.80	-0.47	-1.22	-1.54	-1.88	-1.93	-2.63	-1.88	-1.10	-1.02	-1.40
NOPAT Margin	-527.11%	-322.49%	-1,452.43%	-1,835.89%	-1,024.07%	-1,106.73%	-1,508.79%	-1,081.62%	0.00%	-5,081.66%	0.00%
Net Nonoperating Expense Percent (NNEP)	0.00%	-4.44%	-9.45%	-15.82%	-20.12%	-13.88%	-17.66%	-18.85%	-7.83%	-7.31%	-14.27%
Return On Investment Capital (ROIC_SIMPLE)	-	-7.61%	-12.52%	-20.13%	-20.05%	-28.48%	-50.81%	-72.31%	-24.35%	-16.37%	-32.13%
Cost of Revenue to Revenue	3.19%	0.00%	0.00%	0.00%	1.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	470.07%	391.19%	1,492.65%	1,571.26%	499.50%	712.12%	693.63%	563.49%	0.00%	4,982.58%	0.00%
R&D to Revenue	379.76%	169.50%	682.25%	1,151.44%	1,061.98%	968.92%	1,561.78%	1,081.68%	0.00%	2,376.94%	0.00%
Operating Expenses to Revenue	849.82%	560.69%	2,174.90%	2,722.70%	1,561.47%	1,681.04%	2,255.41%	1,636.01%	0.00%	7,359.52%	0.00%
Earnings before Interest and Taxes (EBIT)	-1.19	-0.65	-1.78	-2.19	-2.71	-2.72	-3.79	-2.70	-1.60	-1.45	-1.99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.16	-0.64	-1.77	-2.18	-2.67	-2.71	-3.76	-2.68	-1.58	-1.43	-1.97
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	5.52	4.95	7.69	3.71	3.61	3.23	5.76	4.93	2.63	3.15
Price to Tangible Book Value (P/TBV)	0.00	5.52	4.95	8.22	3.92	3.89	3.56	6.42	5.26	2.77	3.39
Price to Revenue (P/Rev)	43.39	102.52	121.95	133.15	73.05	49.06	29.08	24.39	46.41	47.27	76.92
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	22.76	33.22	52.72	22.89	122.23	26.90	25.91	553.74	13.31	16.36
Enterprise Value to Revenue (EV/Rev)	0.00	87.81	100.35	118.08	55.82	35.77	20.84	20.96	37.07	31.71	55.91
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.77	-0.87	-0.79	-0.87	-0.88	-0.88	-0.84	-0.91	-0.92	-0.88
Leverage Ratio	0.00	1.04	1.11	1.16	1.04	1.16	1.12	1.27	1.14	1.17	1.21
Compound Leverage Factor	0.00	1.04	1.11	1.15	1.04	1.16	1.12	1.27	1.14	1.17	1.21
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	-6.07%	-3.85%	-4.93%	-4.05%	-5.68%	-7.46%	-14.87%	-8.61%	-6.32%	-9.07%
Common Equity to Total Capital	0.00%	106.07%	103.85%	104.93%	104.05%	105.68%	107.46%	114.87%	108.61%	106.32%	109.07%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	96.02	104.45	22.70	46.92	-1.27	-6.79	-16.11	-5.54	23.68	0.02
Noncontrolling Interest Sharing Ratio	0.00%	-6.64%	-5.29%	-7.17%	-4.05%	-5.86%	-5.10%	-7.45%	0.00%	-5.98%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	66.29	58.27	7.18	29.64	4.24	3.90	2.32	3.68	26.88	10.60
Quick Ratio	0.00	63.02	55.84	6.10	28.15	3.77	3.35	1.56	3.10	24.74	9.56
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.55	-0.73	-1.85	-1.43	-3.10	-0.72	-1.86	-1.41	0.08	-1.74	-1.58
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	-4,397.78%	-11,061.25%	-149,789,100.00%	0.00%	-264,249,800.00%	0.00%	-5,301.53%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.06	0.05	0.08	0.05	0.07	0.07	0.11	0.07	0.05	0.03
Accounts Receivable Turnover	0.00	1.42	2.16	3.30	1.89	1.53	2.17	2.70	2.97	1.97	0.95
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	1.33	1.66	1.82	1.84	2.15	2.68	2.92	2.14	1.46	0.83
Accounts Payable Turnover	0.00	0.23	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	256.66	169.05	110.52	193.54	238.83	167.88	135.17	122.90	185.08	382.99
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	1,567.15	43,614.36	49,441.91	36,095.55	124,019.28	106,483.85	169,715.27	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	-1,310.49	-43,445.31	-49,331.39	-35,902.01	-123,780.45	-106,315.97	-169,580.10	122.90	185.08	382.99
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	1.35	1.24	1.04	1.21	0.15	0.48	0.57	0.03	0.88	0.66
Invested Capital Turnover	0.00	0.29	0.44	0.42	0.82	0.70	0.72	0.88	0.84	0.71	0.34
Increase / (Decrease) in Invested Capital	-1.35	0.26	0.63	-0.11	1.21	-1.20	-0.76	-0.47	-1.18	0.72	0.19
Enterprise Value (EV)	0.00	31	41	55	28	19	13	15	19	12	11
Market Capitalization	12	36	50	62	36	26	18	17	24	17	15
Book Value per Share	$0.00	$0.62	$0.79	$0.51	$0.56	$0.41	$0.32	$0.15	$0.22	$0.27	$0.19
Tangible Book Value per Share	$0.00	$0.62	$0.79	$0.48	$0.53	$0.38	$0.29	$0.14	$0.21	$0.25	$0.18
Total Capital	0.00	6.15	9.75	7.66	9.39	6.76	5.17	2.60	4.52	6.21	4.34
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-4.79	-8.51	-6.62	-8.18	-6.61	-4.69	-2.03	-4.49	-5.33	-3.68
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.04	0.02	0.00	-0.00	0.00	0.00	0.04	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.54	0.43	0.24	0.41	-0.64	-0.31	0.01	-0.52	0.29	0.06
Debt-free Net Working Capital (DFNWC)	0.00	5.34	8.94	6.80	8.53	5.90	4.32	1.97	3.91	5.56	3.68
Net Working Capital (NWC)	0.00	5.34	8.94	6.80	8.53	5.90	4.32	1.97	3.91	5.56	3.68
Net Nonoperating Expense (NNE)	0.39	0.19	0.56	0.64	0.82	0.79	1.17	0.82	0.50	0.44	0.60
Net Nonoperating Obligations (NNO)	0.00	-4.79	-8.51	-6.62	-8.18	-6.61	-4.69	-2.03	-4.49	-5.33	-3.68
Total Depreciation and Amortization (D&A)	0.03	0.02	0.02	0.02	0.03	0.00	0.03	0.02	0.02	0.02	0.02
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	154.38%	105.09%	52.31%	82.47%	-121.85%	-49.79%	1.05%	-99.22%	77.77%	33.17%
Debt-free Net Working Capital to Revenue	0.00%	1,519.23%	2,174.43%	1,464.33%	1,716.15%	1,122.21%	701.17%	279.76%	748.39%	1,509.68%	1,897.66%
Net Working Capital to Revenue	0.00%	1,519.23%	2,174.43%	1,464.33%	1,716.15%	1,122.21%	701.17%	279.76%	748.39%	1,509.68%	1,897.66%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.06)	($0.13)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	0.00	12.89M	15.81M	17.45M	17.55M	17.56M	19.56M	22.23M	24.89M	24.79M	24.79M
Adjusted Diluted Earnings per Share	$0.00	($0.06)	($0.13)	($0.15)	($0.16)	($0.15)	($0.21)	($0.14)	($0.07)	($0.06)	($0.08)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	12.89M	15.81M	12.38M	16.67M	17.51M	18.30M	18.00M	21.38M	24.44M	24.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.06)	($0.13)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	10.77M	13.86M	17.45M	17.55M	17.56M	19.56M	22.23M	24.89M	24.79M	24.79M
Normalized Net Operating Profit after Tax (NOPAT)	-0.80	-0.47	-1.22	-1.54	-1.88	-1.93	-2.63	-1.88	-1.10	-1.02	-1.40
Normalized NOPAT Margin	-527.11%	-322.49%	-1,452.43%	-1,835.89%	-1,024.07%	-1,106.73%	-1,508.79%	-1,081.62%	0.00%	-5,081.66%	0.00%
Pre Tax Income Margin	-783.35%	-450.16%	-2,124.18%	-2,603.06%	-1,471.61%	-1,561.48%	-2,178.51%	-1,550.14%	0.00%	-7,250.67%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Lexaria Bioscience (NASDAQ: LEXX) continues to operate like a development-stage biotech: it has some cash on hand, but it is still losing money and relies on share issuance to fund operations. Over the last several quarters, revenue has been inconsistent and too small to offset a high expense base, while cash has declined sharply from earlier highs.

Cash position remains workable for now. As of Q3 2026, Lexaria held $3.5 million in cash and equivalents plus $142 thousand in short-term investments, with total current assets of $4.1 million.
Equity is still positive. Total common equity was $4.7 million in Q3 2026, which means the balance sheet has not been impaired into negative equity.
Debt levels appear low. Total liabilities were only $437 thousand in Q3 2026, which is modest relative to assets and equity.
Operating cash burn improved versus some prior periods. Q3 2026 operating cash outflow was $1.66 million, better than the much larger losses seen in several earlier quarters.
Revenue remains minimal and uneven. Lexaria reported $0 revenue in Q3 2026 after just $20 thousand in Q2 2026, following a long stretch of small quarterly revenue totals.
Expense structure is still heavy. In Q3 2026, selling, general and administrative expense was $1.02 million and R&D expense was $971 thousand, keeping quarterly operating expenses near $2.0 million.
Noncontrolling interest is material on the equity section. The company reports a negative noncontrolling interest balance, which adds complexity to the capital structure.
Share count has fluctuated meaningfully. Weighted average diluted shares were about 24.8 million in Q3 2026 versus 17.6 million in Q2 2025, reflecting dilution over time.
Net losses remain substantial. Q3 2026 net loss was $2.0 million, and losses have been persistent across the past several years.
Cash has declined sharply from earlier levels. Cash and equivalents fell from $8.1 million in Q1 2025 and $6.5 million in Q2 2025 to $3.5 million in Q3 2026.
The company depends on financing to stay liquid. In several quarters, cash flow was supported by common equity issuance, including $3.47 million in Q1 2026 and $3.04 million in Q2 2026.
Long-term profitability is still not visible. Over the last four years, Lexaria has repeatedly posted operating losses and negative earnings per share, with no clear evidence yet of operating leverage.
Accounts payable jumped sharply at times. In Q1 2026, accounts payable rose to $1.4 million before dropping back, suggesting working capital needs can be volatile.

Bottom line: Lexaria’s balance sheet still shows cash, equity, and limited debt, but the broader trend is not encouraging. The company is still burning cash, posting losses, and funding operations through stock issuance. For retail investors, the key question is whether upcoming clinical or commercial milestones can eventually justify the ongoing dilution and cash use.

07/21/26 09:25 AM ETAI Generated. May Contain Errors.

Lexaria Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lexaria Bioscience's fiscal year ends in August. Their fiscal year 2025 ended on August 31, 2025.

Lexaria Bioscience's net income appears to be on an upward trend, with a most recent value of -$11.91 million in 2025, rising from -$1.93 million in 2015. The previous period was -$5.81 million in 2024. See where experts think Lexaria Bioscience is headed by visiting Lexaria Bioscience's forecast page.

Lexaria Bioscience's total operating income in 2025 was -$11.88 million, based on the following breakdown:

Total Gross Profit: $703.20 thousand
Total Operating Expenses: $12.58 million

Over the last 10 years, Lexaria Bioscience's total revenue changed from $14.70 thousand in 2015 to $705.92 thousand in 2025, a change of 4,701.5%.

Lexaria Bioscience's total liabilities were at $1.57 million at the end of 2025, a 30.1% increase from 2024, and a 2,752.4% increase since 2015.

In the past 10 years, Lexaria Bioscience's cash and equivalents has ranged from $93.41 thousand in 2016 to $10.92 million in 2021, and is currently $1.80 million as of their latest financial filing in 2025.

Over the last 10 years, Lexaria Bioscience's book value per share changed from 0.04 in 2015 to 0.15 in 2025, a change of 294.1%.

Related Companies

Financial statements for NASDAQ:LEXX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexaria Bioscience (LEXX) Financials

Financials Breakdown Chart

Key Financial Trends

Lexaria Bioscience Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexaria Bioscience (LEXX) Financials

Annual Income Statements for Lexaria Bioscience

Quarterly Income Statements for Lexaria Bioscience

Annual Cash Flow Statements for Lexaria Bioscience

Quarterly Cash Flow Statements for Lexaria Bioscience

Annual Balance Sheets for Lexaria Bioscience

Quarterly Balance Sheets for Lexaria Bioscience

Annual Metrics And Ratios for Lexaria Bioscience

Quarterly Metrics And Ratios for Lexaria Bioscience

Financials Breakdown Chart

Key Financial Trends

Lexaria Bioscience Financials - Frequently Asked Questions

When does Lexaria Bioscience's financial year end?

How has Lexaria Bioscience's net income changed over the last 10 years?

What is Lexaria Bioscience's operating income?

How has Lexaria Bioscience's revenue changed over the last 10 years?

How much debt does Lexaria Bioscience have?

How much cash does Lexaria Bioscience have?

How has Lexaria Bioscience's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools